Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 566.00K | 391.69K | 1.50M | 208.38M | 12.62M |
Gross Profit | 566.00K | -1.21M | 121.14K | 208.38M | 12.62M |
EBITDA | -61.27M | -57.69M | -54.17M | 124.40M | -81.12M |
Net Income | -26.43M | -52.34M | -54.17M | 122.83M | -81.04M |
Balance Sheet | |||||
Total Assets | 92.17M | 144.03M | 155.27M | 194.54M | 75.93M |
Cash, Cash Equivalents and Short-Term Investments | 53.08M | 105.83M | 129.00M | 187.80M | 72.03M |
Total Debt | 14.76M | 16.00M | 16.54M | 0.00 | 0.00 |
Total Liabilities | 23.94M | 56.23M | 22.99M | 14.80M | 32.29M |
Stockholders Equity | 68.23M | 87.80M | 132.27M | 179.75M | 43.63M |
Cash Flow | |||||
Free Cash Flow | -56.03M | -45.92M | -56.65M | 118.42M | -51.97M |
Operating Cash Flow | -55.96M | -45.78M | -55.23M | 118.61M | -51.58M |
Investing Cash Flow | 54.59M | -2.58M | -87.88M | -1.82M | 34.65M |
Financing Cash Flow | 622.00K | 30.54M | 180.66K | 904.08K | 47.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $83.29M | ― | -121.65% | ― | -0.71% | -169.29% | |
53 Neutral | $22.32M | ― | -93.19% | ― | 6.96% | 32.32% | |
49 Neutral | $26.17M | ― | -36.31% | ― | 15.73% | 51.00% | |
46 Neutral | C$197.02M | -3.33 | -23.14% | 2.65% | 20.75% | -0.36% | |
39 Underperform | $30.53M | ― | -134.15% | ― | ― | 95.48% | |
36 Underperform | $24.66M | ― | -39.78% | ― | ― | 84.17% | |
27 Underperform | $24.08M | ― | -238.64% | ― | ― | 30.96% |
On July 9, 2025, Ovid Therapeutics held its annual stockholders meeting, where several key proposals were voted on. Stockholders elected directors for a three-year term, approved executive compensation, ratified KPMG LLP as the accounting firm, and authorized a potential reverse stock split, indicating strategic financial adjustments.
The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
On June 23, 2025, Ovid Therapeutics entered into an agreement with Immedica Pharma AB to sell its future royalties related to ganaxolone, a medicine used for treating CDKL5 deficiency disorder, for $7.0 million. This transaction provides Ovid with non-dilutive funding to support its operations, while Immedica gains control over ganaxolone’s intellectual property rights, enhancing its focus on rare diseases.
The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.